- Home
- VENU vs TNGX Comparison
VENU vs TNGX Comparison
Compare VENU & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VENU
- TNGX
- Stock Information
- Founded
- VENU 2017
- TNGX 2014
- Country
- VENU United States
- TNGX United States
- Employees
- VENU N/A
- TNGX N/A
- Industry
- VENU
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- VENU
- TNGX Health Care
- Exchange
- VENU NYSE
- TNGX Nasdaq
- Market Cap
- VENU 313.2M
- TNGX 317.4M
- IPO Year
- VENU 2024
- TNGX N/A
- Fundamental
- Price
- VENU $7.90
- TNGX $1.14
- Analyst Decision
- VENU
- TNGX Strong Buy
- Analyst Count
- VENU 0
- TNGX 7
- Target Price
- VENU N/A
- TNGX $12.33
- AVG Volume (30 Days)
- VENU 20.0K
- TNGX 532.3K
- Earning Date
- VENU 05-15-2025
- TNGX 05-12-2025
- Dividend Yield
- VENU N/A
- TNGX N/A
- EPS Growth
- VENU N/A
- TNGX N/A
- EPS
- VENU N/A
- TNGX N/A
- Revenue
- VENU $17,834,383.00
- TNGX $42,069,000.00
- Revenue This Year
- VENU $91.00
- TNGX N/A
- Revenue Next Year
- VENU $422.18
- TNGX N/A
- P/E Ratio
- VENU N/A
- TNGX N/A
- Revenue Growth
- VENU 41.57
- TNGX 15.17
- 52 Week Low
- VENU $7.05
- TNGX $1.11
- 52 Week High
- VENU $11.15
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- VENU N/A
- TNGX 36.06
- Support Level
- VENU N/A
- TNGX $1.03
- Resistance Level
- VENU N/A
- TNGX $1.56
- Average True Range (ATR)
- VENU 0.00
- TNGX 0.15
- MACD
- VENU 0.00
- TNGX -0.01
- Stochastic Oscillator
- VENU 0.00
- TNGX 17.74
About VENU VENU HOLDING CORPORATION
Venu Holding Corp is an entertainment and hospitality holding company based in Colorado Springs, Colorado. It designs, develops, owns, and operates up-scale music venues, outdoor amphitheaters, and full-service restaurants and bars where music, dining, and luxury experiences converge.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.